AmideBio has leveraged its core manufacturing technology to pursue a series of therapeutic targets that include, ultrastable and ultraconcentrated insulin for T2 diabetes , glucose responsive insulin for T1 and T2 diabetes, solution stable glucagon for hyperinsulinism and similar orphan indications as well as the the development of diagnostics for early detection of T1 diabetes.

PROGRAM

INDICATION

DISCOVERY

PRECLINICAL

IND ENABLING

AB-SCI-0177

T2 DIABETES

AB-GLC-0035

HYPERINSULINISM

AB-GRI-0084

T1/T2 DIABETES

AB-DIG-0014

T1 DIAGNOSTIC